Glycaemic Control in Women With Type 1 Diabetes and Preeclampsia Risk: A Nationwide Cohort Study
- PMID: 40856153
- DOI: 10.1111/1471-0528.18339
Glycaemic Control in Women With Type 1 Diabetes and Preeclampsia Risk: A Nationwide Cohort Study
Abstract
Objective: No large-scale studies exist investigating glycaemic control around conception and preeclampsia risk.
Design: Population-based nationwide cohort study using the National Diabetes Register and other health registers.
Setting: Sweden.
Population: Singleton pregnancies between 2003 and 2019 (N = 1 689 301); 4429 with type 1 diabetes (T1DM) and 1 684 872 without.
Methods: The main exposure was having a pre-gestational diagnosis of T1DM (first diagnosis anytime ≤ 91 days after conception and ≥ 1value of glycated haemoglobin (HbA1c) within ±90 days from conception). Peri-conceptional glycaemic control was categorised using the most recent HbA1c measurement (mmol/mol: < 48; 48-61; 62-75; ≥ 76). Unexposed were women without any diabetes diagnosis (≤ 91 days after conception).
Main outcome measures: Preeclampsia was defined using ICD codes and further categorised according to completed gestational weeks at delivery with preeclampsia diagnosis: early preterm preeclampsia (< 34 + 0), late preterm preeclampsia (34 + 0 to 36 + 6), or term preeclampsia (≥ 37 + 0).
Results: 16.8% of women with T1DM developed preeclampsia, compared to 2.9% of women without diabetes (adjusted RR [aRR] 4.7, 95% CI 4.4-5.0). Preeclampsia risk increased with peri-conceptional HbA1c, from 11.6% in women with HbA1c < 48 mmol/mol to 23.3% in women with HbA1c ≥ 76 mmol/mol. Compared to unexposed women, there was a dose-response relationship between HbA1c and preeclampsia in women with T1DM (HbA1c < 48 mmol/mol aRR 3.4 (2.9-4.0); HbA1c 48-61 mmol/mol aRR 4.6 (4.2-5.1); HbA1c 62-75 mmol/mol aRR 5.7 (5.0-6.5): HbA1c ≥ 76 mmol/mol aRR 6.3 (CI 5.3-7.7)). Compared to unexposed women, the aRR of term preeclampsia was 3.5 times higher (3.1-3.9) in women with T1DM, while the aRR was much higher for early preterm preeclampsia (aRR 7.2: 6.1-8.5) and late preterm preeclampsia (aRR 9.9: 8.8-11.1).
Conclusions: Women with T1DM had a higher risk of preeclampsia, which increased in a dose-response manner with poorer peri-conceptional glycaemic control.
Keywords: diabetes mellitus; hypertension; preeclampsia; pregnancy; pregnancy complications; pregnancy‐induced; type 1.
© 2025 The Author(s). BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
References
-
- G. D. Ogle, F. Wang, A. Haynes, et al., “Global Type 1 Diabetes Prevalence, Incidence, and Mortality Estimates 2025: Results From the International Diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0,” Diabetes Research and Clinical Practice 225 (2025): 112277.
-
- G. A. Gregory, T. I. G. Robinson, S. E. Linklater, et al., “Global Incidence, Prevalence, and Mortality of Type 1 Diabetes in 2021 With Projection to 2040: A Modelling Study,” Lancet Diabetes and Endocrinology 10 (2022): 741–760.
-
- DIAMOND Project Group, “Incidence and Trends of Childhood Type 1 Diabetes Worldwide 1990–1999,” Diabetic Medicine 23 (2006): 857–866.
-
- P. Garner, “Type I Diabetes Mellitus and Pregnancy,” Lancet 346 (1995): 157–161.
-
- H. E. Fadl and D. Simmons, “Trends in Diabetes in Pregnancy in Sweden 1998‐2012,” BMJ Open Diabetes Research & Care 4 (2016): e000221.
Grants and funding
LinkOut - more resources
Full Text Sources
